Thermo Fisher Scientific (BSP:TMOS34) EBIT: R$48,029 Mil (TTM As of Mar. 2026)


BSP:TMOS34 Thermo Fisher Scientific Inc BSP:TMOS34
74 GF Score
Price R$53.25
GF Value R$63.08
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Thermo Fisher Scientific EBIT?

Thermo Fisher Scientific BSP:TMOS34 +7.04% 74 EBIT is R$48,029 Mil as of Mar. 2026. GuruFocus rates BSP:TMOS34 with a GF Score™ of 74/100 and a GF Value™ of R$63.08 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Thermo Fisher Scientific's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was R$10,919 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was R$48,029 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Thermo Fisher Scientific's annualized ROC % for the quarter that ended in Mar. 2026 was 7.47%. Thermo Fisher Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 50.57%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Thermo Fisher Scientific's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.14%.


Thermo Fisher Scientific  (BSP:TMOS34) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Thermo Fisher Scientific's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=40016.9 * ( 1 - 4.04% )/( (498061.765 + 530396.491)/ 2 )
=38400.21724/514229.128
=7.47 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=601998.305 - 48806.692 - ( 55129.848 - max(0, 82866.627 - 156616.78+55129.848))
=498061.765

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=592414.318 - 44990.249 - ( 17027.578 - max(0, 76461.982 - 116703.754+17027.578))
=530396.491

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Thermo Fisher Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=43677.62/( ( (57639.47 + max(28806.097, 0)) + (55737.077 + max(30567.011, 0)) )/ 2 )
=43677.62/( ( 86445.567 + 86304.088 )/ 2 )
=43677.62/86374.8275
=50.57 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(48555.73 + 29597.172 + 14244.834) - (48806.692 + 14784.947 + -1.4551915228367E-11)
=28806.097

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(48133.238 + 28741.882 + 13994.409) - (44990.249 + 15312.269 + 0)
=30567.011

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Thermo Fisher Scientific's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=48028.932/1159460.544
=4.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thermo Fisher Scientific EBIT Related Terms


Thermo Fisher Scientific EBIT Historical Data

* Premium members only.

The historical data trend for Thermo Fisher Scientific's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thermo Fisher Scientific EBIT Chart

Thermo Fisher Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53,026.00 44,905.87 37,596.17 51,413.13 47,611.89

Thermo Fisher Scientific Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11,072.83 11,718.28 11,653.80 13,737.45 10,919.41

BSP:TMOS34 vs DHR, IDXX, A: EBIT Comparison

For the Diagnostics & Research subindustry, Thermo Fisher Scientific's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thermo Fisher Scientific EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Thermo Fisher Scientific's EV-to-EBIT falls into.


BSP:TMOS34
74GF Score
Thermo Fisher Scientific Inc BSP:TMOS34
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thermo Fisher Scientific EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$48,029 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of R$48,029 Mil mean?
Thermo Fisher Scientific (BSP:TMOS34) has a EBIT of R$48,029 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Thermo Fisher Scientific.
Is Thermo Fisher Scientific's EBIT too high?
Thermo Fisher Scientific's current EBIT is R$48,029 Mil. Overall, Thermo Fisher Scientific has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's EBIT compare to DHR and IDXX?
Thermo Fisher Scientific's EBIT of R$48,029 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Thermo Fisher Scientific. Thermo Fisher Scientific's current EBIT is R$48,029 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (BSP:TMOS34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$63.08, compared to a current price of R$53.25 — trading 15.6% below its estimated fair value. The current EBIT is R$48,029 Mil. Thermo Fisher Scientific's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Thermo Fisher Scientific (BSP:TMOS34), the current EBIT is R$48,029 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Thermo Fisher Scientific (BSP:TMOS34) Overvalued in 2026?

Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued. The current stock price of R$53.25 is trading 15.6% below its estimated GF Value™ of R$63.08. GuruFocus considers Thermo Fisher Scientific to be Modestly Undervalued.

Key valuation signals for BSP:TMOS34:

  • EBIT: R$48,029 Mil
  • GF Value™: R$63.08 vs. price of R$53.25 (15.6% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the BSP:TMOS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Thermo Fisher Scientific Business Description

Address 168 Third Avenue, Waltham, MA, USA, 02451
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
74GF Score

Get the complete analysis for BSP:TMOS34

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$53.25
Price
R$63.08
GF Value